论文部分内容阅读
目的探讨静脉应用蔗糖铁治疗血液透析患者肾性贫血的有效性和安全性。方法将我院40例行维持性血液透析治疗的慢性肾衰患者随机分为蔗糖铁组和硫酸亚铁口服组,每组20例。2组患者均联合促红细胞生成素(EPO)治疗,治疗10周后观察患者血红蛋白(Hb)、红细胞(RBC)、红细胞压积(Hct)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)、肝肾功能等的变化情况。结果治疗前静脉组与口服组患者的性别、年龄、体重、Hb、Hct、SP、TSAT及EPO等方面差异无统计学意义(P>0.05)。治疗后患者贫血均有改善,但蔗糖铁组Hb、Hct、SP、TSAT均高于口服组(P<0.05),且无副反应,口服组15%(3/20)出现消化道反应。治疗前后两组患者肝、肾功能等均无明显变化。结论对于伴有缺铁的肾性贫血患者,静脉应用蔗糖铁是安全有效的。
Objective To investigate the efficacy and safety of intravenous administration of sucrose iron in the treatment of renal anemia in hemodialysis patients. Methods 40 patients with chronic renal failure who underwent maintenance hemodialysis in our hospital were randomly divided into two groups: oral sucrose group and ferrous sulfate group, with 20 cases in each group. The patients in both groups were treated with erythropoietin (EPO) for 10 weeks. The levels of Hb, RBC, Hct, SF, transferrin saturation TSAT), liver and kidney function changes. Results There was no significant difference in gender, age, body weight, Hb, Hct, SP, TSAT and EPO before treatment between the venous group and the oral group (P> 0.05). After treatment, patients with anemia improved, but Hb, Hct, SP and TSAT in sucrose group were higher than those in oral group (P <0.05). No side effects were found. 15% (3/20) oral group had gastrointestinal reactions. Before and after treatment, liver and kidney function of the two groups had no significant changes. Conclusion Intravenous iron sucrose is safe and effective for patients with renal anemia associated with iron deficiency.